 AIM ImmunoTech Inc NYSE:AIM closed its third quarter with a 53.7 million balance sheet as the company advances Ampligen as a therapy for locally advanced or metastatic late-stage pancreatic cancer. We are proud of the progress made through the third quarter, said CEO Thomas Equels in a statement. 